Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

BACKGROUND: KRAS mutations may predict poor response to radiotherapy. Downstream events from KRAS, such as activation of BRAF, AKT and ERK, may also confer prognostic information but have not been tested in rectal cancer (RC). Our objective was to explore the relationships of KRAS and BRAF mutation...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Davies, Janine M, Trembath, Dimitri, Deal, Allison M, Funkhouser, William K, Calvo, Benjamin F, Finnegan, Timothy, Weck, Karen E, Tepper, Joel E, O'Neil, Bert H
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2011
Hasła przedmiotowe:
Research
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3180690/
https://ncbi.nlm.nih.gov/pubmed/21910869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1748-717X-6-114
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy